Neogenomics (NEO) reported $727M in revenue for fiscal 2025, +10.1% year on year. That ranks #1983 by revenue among 2853 SEC filers and #361 in Industrials. It posted a net loss of −$108M for the same year. Revenue has grown 13.5% a year on average since 2016 ($232M then). The fiscal 2025 balance sheet shows $1.4B in total assets, $160M in cash and $342M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerIncludingAssessedTax | $727M | +10.1% | FY20252025-12-31 |
| Gross profitGrossProfit | $314M | +8.3% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$116M | −$23.8M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$108M | −$29.0M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $5.2M | −25.5% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $27.0M | −34.2% | FY20252025-12-31 |
| Total assetsAssets | $1.4B | −17.0% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $837M | −7.3% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $160M | −56.5% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $342M | +0.4% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $187M | −$17.1M | Open → |
| Q2 20262026-06-30 | $202M | $2.2M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Neogenomics Inc
- Ticker
- NEO
- Exchange
- Nasdaq
- SIC classification
- Services-Testing Laboratories (8734)
- Fiscal year end
- 12-31
- CIK
- 0001077183
Filings
- 10-QJul 28, 2026Open filing →
- 10-QApr 28, 2026Open filing →
- 10-KFeb 17, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Wheels Up ExperienceUP | $736M | −$294M |
| SFLSFL | $733M | −$26.4M |
| Willis Lease FinanceWLFC | $730M | $114M |
| NeogenomicsNEO | $727M | −$108M |
| Mistras GroupMG | $724M | $16.8M |
| Power Solutions InternationalPSIX | $722M | $114M |
| Martin Midstream PartnersMMLP | $716M | −$14.7M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Neogenomics — Key figures |url=https://companiesranked.com/en/company/neogenomics |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Neogenomics — Key figures. CompaniesRanked. https://companiesranked.com/en/company/neogenomicsBibTeX
@misc{companiesranked-en-company-neogenomics-2026,
author = {{CompaniesRanked}},
title = {{Neogenomics — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/neogenomics}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001077183-26-000010 · February 17, 2026
{{cite web |title=Neogenomics — Key figures — 10-K (0001077183-26-000010) |url=https://www.sec.gov/Archives/edgar/data/1077183/000107718326000010/neo-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-17}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.